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Summary
The prototypes for tumor targeting with radiolabeled
peptides are derivatives of somatostatin. Usually,
they primarily have high affinity for somatostatin
receptor subtype 2 (sst2), and they have moderate af-
finity for sst5. We aimed at developing analogs that
recognize different somatostatin receptor subtypes
for internal radiotherapy in order to extend the present
range of accessible tumors. We synthesized DOTA-
octapeptides based on octreotide by replacing Phe3
mainly with unnatural amino acids. The affinity profile
was determined by using cell lines transfected with
sst1–5. Internalization was determined by using
AR42J, HEK-sst3, and HEK-sst5 cell lines, and biodis-
tribution was studied in rat tumor models. Two of the
derivatives thus obtained showed an improved bind-
ing affinity profile, enhanced internalization into cells
expressing sst2 and sst3, respectively, and better
tumor:kidney ratios in animals.
Introduction
The tetradecapeptide somatostatin (SS-14) is of little
therapeutic value despite its broad spectrum of biolog-
ical actions, as it has a short half-life in vivo. Conforma-
tional analyses and structure-function studies on so-
matostatin analogs have indicated that the sequence
required for biological activity consists of the b turn frag-
ment Phe-Trp-Lys-Thr, which corresponds to residues
7–10 of SS-14 [1]. Many somatostatin analogs with
smaller and more rigid rings have been synthesized in
the search for compounds with enhanced and pro-
*Correspondence: hmaecke@uhbs.chlonged activity. Two lead compounds emerged from
this research, the hexapeptide L-363,301 [1] and the oc-
tapeptide octreotide (Sandostatin, SMS 201-995) [2].
One unintended consequence of such structural simpli-
fication, which was carried out before the discovery of
multiple receptor subtypes, was the loss of broad-spec-
trum binding affinity. The cloning of the five somato-
statin receptors (sst1–sst5) [3] has increased the un-
derstanding of somatostatin receptor structure and
function. It also revealed that the short-chain synthetic
analogs of somatostatin have high affinity for somato-
statin receptor subtype 2 (sst2), moderate to low affinity
for sst3 and sst5, and no or very low affinity for sst1
and sst4.
In nuclear oncology, the prototypical tracers used for
in vivo receptor scintigraphy and targeted radionuclide
therapy are derivatives of somatostatin. The molecular
basis for their use is the overexpression of somatostatin
receptors on a variety of human tumors, especially neu-
roendocrine tumors and their metastases [4, 5]. The
majority of human sst-positive tumors simultaneously
express multiple sst subtypes, although there is a con-
siderable variation in sst subtype expression between
different tumor types and among tumors of the same
type. Some of these differences are also due to the
method used for investigating the occurrence of ssts
[6]. Most of the hitherto available data on somatostatin
receptor expression in human tumors originated from
mRNA detection, but more recently several groups pro-
vided information on sst subtype protein expression [5,
7, 8]. Undoubtedly, subtype 2 is the most frequently ex-
pressed subtype in a majority of cancers. Nevertheless,
in a significant number of tumors, sst2 is absent or
expressed only in low density, whereas other ssts are
present. For instance, frequent expression of sst1,
sst2, sst3, and sst5 was found in gastro-entero-pancre-
atic tumors (GEP) [8], in medullary thyroid cancers (MTC)
[9], and in ovarian cancers [10]. A predominant expres-
sion of sst3 was discovered in inactive pituitary adeno-
mas, thymomas, and pheochromocytomas [5, 11, 12].
Human lung tumors were shown to overexpress sst2,
sst3, and sst5 [13]. The considerable heterogeneity in
the expression of individual ssts within and between dif-
ferent tumors provides evidence of the need for tracers
that can target more than one sst in vivo.
The predominant expression of sst2 in human tumor-
ous tissues forms the basis for the successful clinical
application of radiolabeled octapeptide somatostatin
analogs in the imaging of sst-positive tumors. The clas-
sical radioactive somatostatin analogs used for the
in vivo visualization and treatment of human tumors are
derivatives of octreotide, and the standard for scintigra-
phy is [111In-DTPA]-octreotide (Octreoscan). Although
remote from the pharmacophore, the addition of a metal
complex to the N terminus of octreotide led to some loss
in binding affinity, especially to sst5, but also to sst3 and
sst2 [14]. Another derivative developed for nuclear med-
icine applications is [DOTA,Tyr3]-octreotide (DOTA-
TOC), a conjugate that can be labeled with therapeutic
radionuclides (e.g., 90Y or 177Lu); despite the selective
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Compound Hsst1 Hsst2 Hsst3 Hsst4 Hsst5
SS-28 3.4 6 0.3 2.7 6 0.2 4.4 6 0.4 3 6 0.1 3.4 6 0.3
MIII-1 >10,000 20 6 2.2 27 6 8 >1,000 58 6 22
MIII-2 >10,000 11.4 6 1.7 389 6 136 >10,000 204 6 92
MIII-3 >1,000 3.3 6 0.2 26 6 1.9 >1,000 10.4 6 1.6
MIII-4 >10,000 25 6 1.0 133 6 68 >1,000 98 6 12.5
MIII-5 >10,000 3.1 6 0.3 12 6 1.0 455 6 65 6 6 1.8
MIII-6 >10,000 22 6 9 205 6 43 >1,000 648 6 165
MIII-7 >10,000 17 6 6.6 617 6 192 >1,000 647 6 129
MIII-8 >10,000 47 6 6.5 131 6 69 >1,000 75 6 45
MIII-9 >1,000 53 6 16 649 6 187 >1,000 >1,000
MIII-10 >10,000 85 6 15 >1,000 >1,000 315 6 105
MIII-11 >1,000 38 6 2.0 52 6 15 >1,000 283 6 152
MIII-12 >10,000 39 6 8.5 290 6 160 >1,000 65 6 7.0
MIII-13 >10,000 625 6 25 >1,000 >1,000 495 6 105
MIII-14 >10,000 4.0 6 1.3 190 6 10 >1,000 650 6 250
MIII-15 >10,000 190 6 50 >1,000 >1,000 775 6 225
MIII-16 >10,000 12.3 6 4.7 132 6 18 960 6 10 34 6 3.0
MIII-17 >10,000 14 6 1.5 22.7 6 6.2 >1,000 137 6 8.8
MIII-18 >1,000 161 6 76 102 6 53 187 6 30 >1,000
MIII-19 >1,000 21 6 1.0 47 6 17 691 6 99 20 6 9.0
MIII-20 >1,000 93 6 12 18 6 1.0 >1,000 461 6 163
MIII-21 >1,000 890 6 74 119 6 38 >1,000 >1,000
MIII-22 >10,000 >1,000 >10,000 >10,000 >1,000
MIII-23 >10,000 >1,000 >1,000 >1,000 >1,000
MIII-24 >10,000 285 6 35 300 6 130 >1,000 335 6 5
IC50 values are expressed as mean 6 SEM (nR 3); SS-28 is used as control. All compounds were complexed with either Y
III or InIII.binding affinity only to sst2, this compound has been
used clinically for about a decade [15]. Two other
octreotide derivatives, lanreotide [16] and vapreotide
[17], have been developed as well. These octapeptides
have an improved binding affinity profile, but their
metal-chelator conjugates display satisfactory affinity
only to sst2 and sst5 [14].
Octreotide has been a subject of extensive structural
studies, including NMR [18] and X-ray diffraction [19].
Taken together, these studies have demonstrated that
octreotide exists in solution in two conformational fam-
ilies, differing mainly by the conformation of the C-termi-
nal tail. The molecule adopts an overall antiparallel
b sheet conformation, with a type II0 b turn centered at
the D-Trp4-Lys5 region. In one conformational family,
the residues after this b turn continue the b sheet struc-
ture, and in the second family, the residues after the
b turn adopt a 310 helical conformation. X-ray data of
chelator-conjugated and metallated octapeptides are
not yet available. 1H- and 13C-NMR data in solution are
in agreement with the fast equilibrium of two predomi-
nant conformations, a helical and a b sheet structure,
as in octreotide [20]. All of the peptidic analogs of
octreotide conserve the critical sequence D-Trp4-Lys5,
and only subtle modifications have been done to the
side chain amino acids of this b turn (Phe3 and Thr6)
[21]. Among the clinically used analogs of somatostatin
(octreotide, lanreotide, and vapreotide) the only modifi-
cation carried out in the third position has been the sub-
stitution of Phe3 (in octreotide) with Tyr3 (in lanreotide
and vapreotide). Since this substitution is accompanied
by other structural changes at the C terminus (Thr-NH2 in
lanreotide, Trp-NH2 in vapreotide versus Thr(ol) in oc-
treotide) and/or the N terminus (D-2-Nal in lanreotide in-
stead of D-Phe in octreotide and vapreotide), as well as
at the sixth residue (Thr in octreotide replaced by Val inlanreotide and vapreotide), it is difficult to assess the al-
terations in the binding affinity profile. Still, a direct com-
parison of the effects produced by the replacement of
Phe3 with Tyr3 is noticeable on the metal-chelator con-
jugates YIII-DOTA-octreotide (YIII-DOTA-OC) and YIII-
DOTA-[Tyr3]-octreotide (YIII-DOTA-TOC) [14] (also see
Table 1). The more hydrophilic conjugate with Tyr on
the third position has increased binding affinity for
sst2, but it has decreased binding potency to sst3
and sst5.
Based on these structural and empirical data, we as-
sumed that modifications at this position in metal-com-
plexed DOTA derivatives of octreotide might modulate
the affinity profile to sst3 and sst5. Our premise was
that bulky aromatic residues would improve the binding
affinity for sst3 and sst5 without compromising the bind-
ing potency to sst2. The generation of radioactive conju-
gates with a broader affinity profile would not only lead
to an extension of the present range of targeted cancers,
but it would also mean an increased dose of radioactiv-
ity to the tumor, given the presence of different receptor
subtypes on the same tumor cell or in the same tumor
entity.
In this paper, we describe the synthesis and pharma-
cological evaluation of a small library of metal-DOTA-
peptides derived from octreotide with modifications at
the third amino acid residue. We have already reported
the first compound resulting from this library,
[111In/90Y-DOTA]-NOC, which has improved biological
properties and is currently in clinical trials [22].
Results and Discussion
The DOTA-somatostatin analogs 1–24 (Figure 1) ob-
tained by systematic modification of aa3 in octreotide
were synthesized by parallel synthesis on solid phase
Somatostatin-Based Radiopeptides
1083Figure 1. Structural Formulae of Conjugates
1–24by using the Fmoc/tBu strategy and the 2-chloro-trityl-
chloride linker. After cleavage from the resin, cyclization
in solution, and total deprotection, the crude products
were obtained in 25%–30% yield based on the first
Fmoc cleavage. All peptide conjugates had a purity of
>97%, confirmed by RP-HPLC analysis. In each case,
the ESI-MS spectra consisted of a major [M+2K]2+ ion
peak and two minor peaks corresponding to [M+K]+
and [M+3K]3+ ions (Table S1, see the Supplemental
Data available with this article online). Metal-ion-com-
plexed DOTA-peptides were characterized by HPLC,
MS-ESI, and by the retained affinity for the somatostatin
receptors. Labeling with 111In was performed in acetate
buffer (pH 5, 0.4 M) by heating at 95C for 25 min, afford-
ing >99% labeling yields at a specific activity of >37
GBq/mmol peptide.
The partition coefficients of the 111/115In-labeled deriv-
atives 1–24 between aqueous (PBS, pH 7.4) and organic
(octanol) layers were determined by using the shake
flask method. The results are displayed in Figure 2; the
most lipophilic compound is 111/115In-20, and the most
hydrophilic ones are 111/115In-22 and -23.
Table 1 shows the IC50 values of the conjugates stud-
ied in this work as their YIII- or InIII-complexed versionsfor the five ssts. The values were obtained by performing
complete displacement experiments with the universal
somatostatin radioligand [125I][Leu8, D-Trp22, Tyr25]-
somatostatin-28 on membranes from cells expressing
the receptor subtypes and were compared to those of
SS-28.
Internalization studies were performed on AR42J rat
pancreatic tumor cells and on HEK cells stably express-
ing sst3 and sst5 receptors, respectively. The uptakes in
the first two cell lines after a 4 hr incubation with the ra-
diopeptides are shown in Table 2. These values repre-
sent specific accumulation, i.e., the difference between
total uptake and nonspecific accumulation in the pres-
ence of excess nonradioactive derivatives.
We arranged compounds 1–24 in various classes ac-
cording to the nature of the amino acid in the third posi-
tion of the peptide sequence. The following discussion
concentrates on these categories.
Phe Derivatives
Comprising the parent compound, DOTA-octreotide,
are six conjugates bearing a phenylalanine derivative
in the third position of the peptide: 1, 8, 9, 10, 11, and
12. In the homolog series 9, 1, and 8, no improvement
Chemistry & Biology
1084Figure 2. Schematic Illustration of the Parti-
tion Coefficient Values for the 111/115In-
Labeled Conjugates 1–24either in binding affinity or in internalization occurs by
varying the length of the side chain. Although the
phenylglycine residue was previously successfully
employed in this position of the b turn in the cyclohexa-
peptide analog of somatostatin SOM-230 [23], its incor-
poration in DOTA-octapeptide 9 caused a complete loss
of affinity for sst3 and sst5, and a 2.5-fold drop for sst2.
The superior Phe homolog derivative 8 retained some
affinity for sst2, sst3, and sst5, but this affinity was lower
than that of 1. Also, the internalized amount in cells
expressing the rat sst2 receptor (AR42J) is lower com-
pared to 1. The two halogeno-Phe derivatives 11 and
12, while displaying comparable lipophilicities, the same
binding affinities to sst2, and similar amounts of internal-
ized radiopeptide in AR42J cells at 4 hr, differ signifi-
cantly in their binding potencies for sst3 and sst5,
respectively. In-11 had higher binding affinity for sst3
than In-DOTA-octreotide, and it also had a superior
accumulation in HEK-sst3 cells. Derivative 10, the most
lipophilic of this series, had the highest accumulation in
AR42J cells but the lowest sst2 binding affinity among
the six conjugates of this group.
Table 2. Internalization of 111In-Labeled Peptides 1–24 in AR42J
Cells Expressing Sst2 and in HEK Cells Expressing Sst3 after a 4 hr
Incubation at 37C
Radiopeptide
Percentage
Internalized
in AR42J Cells
Percentage
Internalized in
HEK-Rsst3 Cells
111In-1 6.1 6 0.5 1.8 6 0.7
111In-2 11.5 6 1.8 0.8 6 0.2
111In-3 25.0 6 1.5 16.3 6 1.9
111In-4 0.9 6 0.3 0.5 6 0.2
111In-5 17.2 6 1.9 24.3 6 0.9
111In-6 1.1 6 0.8 <0.1
111In-7 1.5 6 0.3 <0.1
111In-8 1.9 6 0.6 2.0 6 0.1
111In-9 0.7 6 0.4 0.3 6 0.1
111In-10 12.7 6 1.2 <0.1
111In-11 3.7 6 0.3 5.3 6 0.1
111In-12 5.3 6 0.7 1.2 6 0.1
111In-13 <0.1 <0.1
111In-14 5.0 6 0.4 1.2 6 0.2
111In-15 0.8 6 0.2 <0.1
111In-16 5.3 6 0.3 <0.1
111In-17 7.2 6 0.6 12.6 6 1.2
111In-18 0.5 6 0.3 <0.1
111In-19 2.7 6 0.4 6.8 6 0.3
111In-20 2.4 6 0.5 12.1 6 1.0
111In-21 <0.1 0.8 6 0.5
111In-22 <0.1 <0.1
111In-23 <0.1 <0.1
111In-24 0.6 6 0.3 <0.1
The results are expressed as % specific internalized from the total
added radioactivity per one million cells (mean 6 SD; n = 3).Tyr Derivatives
The presence of a weak (-I, conjugate 14) and a strong
(-NO2, conjugate 15) electronic deactivator, respec-
tively, on the Tyr ring in the ortho position relative to
the phenolic OH causes an increase in the pKa values
of these residues (data not shown). This is reflected in
the partition coefficients, which increase in the order
2R 14 >> 15. Apparently, a more acidic residue in this
position is not beneficial either to the binding affinities
to any of the ssts or to the internalization into sst2- or
sst3-expressing cells; 111/115In-15 shows a net inferior
biological profile when compared with 111/115In-DOTA-
TOC (111/115In-2). Using the same reference, 111/115In-
14 has a lower internalization rate in AR42J cells but
an improved sst2 affinity. This result does not corrob-
orate the previous findings of Hofland et al. [24] on
[DOTA,125I-Tyr3]-octreotide, which showed an in-
creased uptake in sst-expressing cells and tissues.
Heterocyclic Side Chain Derivatives
Seven residues with a heterocyclic side chain have been
introduced in the third position of octreotide: two pyri-
dine derivatives (6 and 7), a thiophene (17), a benzothio-
phene (5), an indole (16), a benzthiazole (18), and a piper-
idine side chain residue (23). Undoubtedly, the best
biological profile in this series belongs to MIII-5, the
most lipophilic of this group. Moreover, it also shows
a significant increase in binding affinity for sst2. The in-
ternalizations in sst2- and sst3-expressing cells mirror
these results. Its N analog (16) shows comparable lipo-
philicity, but significantly lower potency on sst2 and
sst5, as well as a dramatic drop of binding affinity and in-
ternalization rate toward sst3. Interestingly, the some-
what more hydrophilic related conjugate 18 fails in all bi-
ological assays. The thiophenylalanine derivative 17 has
a reasonable sst2 and sst3 binding profile and a moder-
ate rate of internalization in both cell lines studied. The
two pyridinylalanine derivatives, 6 and 7, preserve a sat-
isfactory affinity for sst2, but they induce poor endocy-
tosis in AR42J cells. In the structure-activity investiga-
tions done by Hocart et al. [25] in their search for
somatostatin antagonists, the substitution of 3-pyridyla-
lanine in this position produced an antagonist with mar-
ginal affinity for sst2 (291 nM). The worst derivative of
this series is the most hydrophilic one, bearing a piperi-
dylalanine residue in the third position (23).
Polyaromatic Side Chain Derivatives
Two naphthylalanine derivatives (3 and 4), a diphenylala-
nine (13), an anthranylalanine (19), and a pyrenylalanine
(20) have been employed instead of Phe3 in octreotide.
The complexed version of 3 has incontestably the best
Somatostatin-Based Radiopeptides
1085Figure 3. Comparison in Cellular Retention
after 2 hr of Internalization of 111In-3 and
111In-5 in AR42J Cells and in HEK Cells
Expressing sst3
The values represent the percentage re-
tained in the cell of the total amount internal-
ized (mean 6 SD, n = 3).biological profile of this group [22]. The binding potency
of this compound on sst2 and sst3 is complemented by
good internalization rates in cells expressing these re-
ceptors. It has also a superior binding affinity for sst5
compared with the parent conjugate 1. Interestingly,
the 2-Nal3 conjugate (4) turned out to be inferior in all as-
says, a result difficult to explain, given the very small
structural difference between the two compounds. It
has moderate binding affinity for sst2, comparable
with that of 1, and shows insignificant accumulation in
AR42J cells after a 4 hr incubation at 37C. The di-
phenyl-substituted derivative 13, one of the most lipo-
philic conjugates of this series, completely loses binding
affinity for all ssts and thus the capacity to activate the
internalization of the receptors as well.
The bulkiest and most lipophilic conjugate, 20, has
one of the highest affinities to sst3, and it also induces
one of the highest internalization rates in HEK-sst3 cells.
The second bulkiest conjugate, 19, has lower affinity for
sst3, but higher affinity for sst5, while it also maintains
a good binding affinity for sst2.
Aliphatic Side Chain Derivatives
The three aliphatic side chain residues Ser (21), Lys (22),
and cyclohexylalanine (24) were employed in the third
position for reasons of comparison and to prove the
necessity of an aromatic residue in this location. All of
these derivatives lost their binding affinity for all sst sub-
types and did not internalize in either sst2- or sst3-
expressing cells. Previous Ala-scan studies [26] on SS-14
have also shown that the replacement of Phe7 (corre-
sponding to Phe3 in octreotide) by an Ala residue leads
to a drop of w90% in the ability to inhibit growth hor-
mone release in vitro. For derivative 22, as for the
above-mentioned conjugate 23, another reason for the
loss of potency might be due to the additional positive
charge.
Summarizing the above-presented data, very subtle
modifications in the region of the b bend have profound
effects on the pharmacological profile. Even if the bind-
ing affinity and the capacity to internalize are two dis-tinct features of a G protein-coupled receptor that do
not necessarily correlate [27], most of the ligands with
reasonable-to-good binding affinity reported herein
also induce internalization to a higher or lower extent.
Two intriguing exceptions to this ‘‘rule’’ are the metal-
complexed derivatives 4 and 10, as depicted above.
Given the complex signal transduction mechanisms of
somatostatin receptors [27], it is difficult to explain these
results; however, they are probably due to the different
agonist abilities (partial or total agonist) of these deriva-
tives. Substantial evidence points to ligand composi-
tion, receptor subtype, and the cell line used for trans-
fection of receptor DNA as critical factors in the
intracellular routing and retention of somatostatin and
its analogs [28].
Generally, the bulky and lipophilic residues employed
instead of Phe3 increase the binding affinity for sst3 and
also activate the internalization of this receptor. The best
conjugates for this receptor were the metal-complexed
3, 5, 17, 19, and 20 conjugates. Some of them also en-
hance the potency of binding to sst5 (3, 5, 16, and 19).
Nevertheless, the broadest affinity profile in this se-
ries, supplemented by a good activation of internaliza-
tion in sst2- and sst3-expressing cell lines, respectively,
was shown by the metal-complexed conjugates 3 and
5. We previously reported the biological evaluation
of 111/115In-3 (111/115In-DOTA-NOC) [22] compared to
111/115In-labeled DOTA-TOC and DOTA-OC. This com-
pound is currently being clinically studied in a group of
metastasized thyroid cancer patients not showing ra-
dioiodine uptake anymore; compared to the other radio-
labeled somatostatin analogs in clinical use, it shows
improved imaging properties [29].
We compared 111In-5 with 111In-3 in cellular retention
tests in AR42J and HEK-sst3 cells (Figure 3), and we
found a similar behavior in both cell lines. Both com-
pounds display a higher retention of the internalized
fraction in the sst3-expressing cells than in sst2-
expressing cells, which is probably due to the difference
in receptor dynamics: after agonist-induced internaliza-
tion, sst2 receptors have been shown to recycle rapidly
Chemistry & Biology
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nalization in HEK Cells Expressing sst5
Agonist-induced receptor internalization:
HEK cells stably expressing human sst5
were exposed for 30 min to SS-14, InIII-3,
and InIII-5. Cells were then fixed, processed
for immunofluorescence, and examined by
confocal microscopy. Shown are represen-
tative images from one of three independent
experiments performed in duplicate. The
scale bar is 20 mm.to the plasma membrane, whereas sst3 receptors suffer
lysosomal degradation and hence do not recycle rapidly
to the plasma membrane [30]. Nevertheless, the two
conjugates behave differently in immunocytochemical
internalization studies in HEK cells stably expressing hu-
man sst5 receptors (Figure 4). Although it has previously
been shown by Roth et al. [28] that in sst5-transfected
HEK cells receptor endocytosis is promoted only by
the octacosapeptide (SS-28), and not by SS-14, in our
assay SS-14 triggers receptor internalization after 30
min of incubation at 37C. Also, InIII-3 induces sst5 inter-
nalization in HEK-sst5 cells to a lower extent than SS-14,
while InIII-5 activates no receptor endocytosis in these
cells. In our radioligand assays of internalization in
HEK-sst5 cells, no uptake has been found for any of
the radiopeptides, including 111In-3 and -5 (data not
shown).
In vitro internalization studies are generally used as
a predictor of in vivo tumor or sst-positive tissue accu-
mulation [31]. Despite the negative results obtained inthe sst5 internalization assays, 111In-5 has a 2-fold
higher accumulation than 111In-3 in CA20948 rat pancre-
atic tumor (Figure 5A) at 4 hr after injection. This ratio be-
tween the two ligands is also maintained 24 hr after in-
jection, and it slightly decreases after 48 hr. As this
type of tumor has been shown to express several ssts
[32], sst homo- and heterodimerization may alter both li-
gand affinity and signaling efficacy of somatostatin re-
ceptors in these tumor cells [33, 34]. In the AR42J tumor,
the two ligands accumulate in a similar manner (Fig-
ure 5B) as a consequence of the sole sst2 presence in
this tissue [35]. Both radioligands have favorable tu-
mor:kidney ratios in both rat tumor-bearing models, as
shown in Figure 5 [22]. This is an important parameter
in targeted radiotherapy since the kidney is the dose-
limiting organ [36].
Overall, in addition to DOTA-NOC (3), conjugate 5
(named DOTA-BOC), originating from the same library
of DOTA-octreotide derivatives with modifications at
the third residue, displays very promising preclinicalFigure 5. Comparison between 111In-3 and
111In-5 in Tumor Uptake and Tumor:Kidney
Ratios
(A and B) Comparison of the tumor uptake ki-
netics and the tumor:kidney ratios (mean 6
SD) between 111In-3 and 111In-5 in two animal
models: (A) CA20948 and (B) AR42J (*p <
0.001, compared with the uptake of the other
compound; nR 3).
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logical evaluation of the Thr8 modification of these con-
jugates (DOTA-NOC-ATE and DOTA-BOC-ATE), which
also show encouraging in vitro and in vivo biological
profiles but a somewhat faster tumor washout com-
pared with 111In-3 and 111In-5 [37]. As mentioned, this
type of radioligand might be used as an imaging agent
to predict the usefulness of a therapy with cold octreo-
tide (Sandostatin) or lanreotide (Somatuline) rather
than with OctreoScan, which has a much less adequate
binding profile for this purpose. Since there is no radio-
ligand for SOM230—a cyclohexapeptide that has high
binding affinity for sst1, sst2, sst3, and sst5 and is cur-
rently under evaluation in phase 1 clinical trials [38]—
these radioligands may also be candidates for identify-
ing patients eligible for SOM230 treatment.
Significance
Peptide receptor-mediated radionuclide imaging and
targeted therapy are emerging fields in oncology.
The prototypical peptides are derivatives of somato-
statin. Nevertheless, the clinically used derivatives pri-
marily have affinity for sst2. Although this receptor is
overexpressed in a variety of tumors, there are several
malignancies with other ssts being expressed in
higher density. We designed and synthesized a new,
to our knowledge, series of DOTA-octreotide deriva-
tives by exchanging the third residue in octreotide
principally with a variety of aromatic side chain amino
acids. We chose this position due to its involvement in
the critical b turn of this molecule and to the empirical
observations on the pharmacological profile of two
DOTA derivatives used in the clinic. The small library
of compounds thus obtained is not only a useful struc-
ture-activity investigational tool, but it also provides
two new, to our knowledge, derivatives with improved
pharmacological properties. DOTA-[1-Nal3]-octreotide
(3) and DOTA-[BzThi3]-octreotide (5), when labeled
with 111In, 90Y, 177Lu, or 68Ga, have the broadest affinity
profile among the radioligands used in the clinic and
can efficiently target sst2, sst3, and sst5. This means
not only an increase of the present range of targeted
tumors, but also an enhanced cytotoxic radioactive
dose to the same tumor expressing several ssts.
Experimental Procedures
Abbreviations
The nomenclature for the somatostatin receptor subtypes (ssts) is in
accordance with the recommendations of IUPHAR [3]. Abbrevia-
tions of the common amino acids are in accordance with the recom-
mendations of IUPAC-IUB [39]. Additional abbreviations: 1 (or 2)-
Nal, 1 (or 2)-naphthylalanine; Thi, (2-thienyl)-alanine; 3 (or 4)-Pya, 3
(or 4)-pyridylalanine; hPhe, homophenylalanine; (4-I) Phe, 4-iodo-
phenylalanine; (4-iPr) Phe, 4-isopropyl-phenylalanine; (3-NO2) Tyr,
3-nitro-tyrosine; (4-Pip) Ala, 4-piperidinyl-alanine; BzThi, 3-benzo-
thienylalanine; Cha, cyclohexylalanine; Antra, anthranylalanine;
Pyra, 1-pyrenylalanine; PhGly, phenylglycine; DOTA, 1,4,7,10-tetra-
azacyclododecane-1,4,7,10-tetraacetic acid; DOTA(tBu)3 (prochela-
tor), 1,4,7,10-tetraazacyclododecane-1,4,7-tris(tertbutyl acetate)-10-
acetic acid; DCM, dichloromethane; DIC, diisopropylcarbodiimide;
DIPEA, diisopropylethylamine; DMF, dimethylformamide; HOBt,
N-hydroxybenzotriazole; HATU, O-(7-azabenzotriazol-1-yl)-N, N,
N0, N0-tetramethyluroniumhexafluorophosphat; TFA, trifluoroaceticacid; TFE, trifluoroethanol; TIS, triisopropylsilane; TNBS, 2,4,6-
trinitrobenzenesulphonic acid.
Materials
All chemicals were obtained from commercial sources and were
used without further purification. H-Thr(tBu)ol-(2-chlorotritylchlor-
ide) resin was obtained from Advanced ChemTech (Louisville, KY),
and most Fmoc (9-fluorenylmethoxycarbonyl) amino acids were
purchased from NovaBiochem AG, La¨ufelfingen (Switzerland) and
Neosystem (France). The reactive side chains of the amino acids
were masked with one of the following groups: Cys, acetamido-
methyl; Lys, t-butoxycarbonyl; Thr, t-butyl; Trp, t-butoxycarbonyl.
The prochelator DOTA(tBu)3 was synthesized according to Heppeler
et al. [40]. Analytical RP-HPLC was carried out on a Hewlett Packard
1050 HPLC-system equipped with a multiwavelength-detector and
a flow-through Berthold LB506C1 g-detector. Preparative HPLC
was done on a Bischof HPLC system (Metrohm AG, Switzerland)
with HPLC-pumps 2250 and a Lambda 1010 UV-detector. Quantita-
tive g-counting was performed on a COBRA 5003 g-system well
counter from Packard Instrument Company (Switzerland). Electro-
spray ionization-mass spectrometry (ESI-MS) was carried out with
a Finnigan SSQ 7000 spectrometer (Bremen, Germany). 111InCl3
was obtained from Mallinckrodt Medical (Petten, The Netherlands).
Peptide-Conjugate Synthesis
The peptide-chelator conjugates were synthesized by parallel stan-
dard Fmoc-solid-phase synthesis [41] on 2-chlorotritylchloride resin
(substitution 0.8 mmol/g) on a Rink Engineering peptide-synthesizer
Switch 24 (RinkCombichem, Bubendorf, Switzerland). A 3.0 equiva-
lent excess of the protected amino acids based on the original sub-
stitution of the resin was used. The couplings were mediated by DIC
and HOBt in DMF for 1 hr and were monitored by the qualitative nin-
hydrin or TNBS test. Fmoc removal was achieved with 20% piperi-
dine in DMF in two successive 10 min treatments. The last step on
the solid phase was the coupling of the prochelator DOTA(tBu)3 to
the N terminus of the peptide for 2 hr, by using HATU as an activating
agent. The fully protected conjugates were then cleaved from the
resin support by using a 1% TFA in DCM solution also containing
H2O (0.5% v/v) and TFE (20% v/v) as scavengers (30 ml cleavage
cocktail/mmol equivalent resin). After coevaporation with toluene
and drying in a desiccator, the crude protected peptide conjugates
were cyclized in aqueous MeOH by the addition of iodine (10 equiv-
alents of a 0.25 M I2 solution). Thirty minutes later, a 0.5 M solution of
ascorbic acid was added to quench the excess of iodine. For com-
plete deprotection, the dried, cyclized peptide conjugates were
dissolved in TFA with TIS (3% v/v), thioanisole (3% v/v), and H2O
(5% v/v) as scavengers (15 ml/mmol). After a 4 hr incubation at
room temperature, the crude products were precipitated with cold
diethyl ether.
Purification and Characterization of Peptide Conjugates
The crude conjugates were purified by preparative RP-HPLC by us-
ing an Interchrom Uptisphere 5ODB C18 column (250 3 21.2 mm)
and a linear gradient from 20% to 50% solvent B (solvent A, 0.1%
TFA/water; solvent B, acetonitrile) over 25 min at a flow rate of 15
ml/min. Detection was done at 254 nm. All compounds were lyoph-
ilized after purification and characterized by ESI-MS and HPLC. Pure
compounds were identified by analytical multiwavelength RP-HPLC
with a CC250/4 Nucleosil 120-3C18 column from Macherey-Nagel
by using a linear gradient from 10% B to 60% B over 40 min at
a flow rate of 0.75 ml/min (solvent A, 0.1% TFA/water; solvent B,
acetonitrile).
Formation of Metal Complexes
The DOTA-SRIF-analogs were complexed either with InCl3 (anhy-
drous) or Y(NO3)3$5 H2O, as described by Wild et al. [22]. The radio-
labeling of these peptide conjugates was also done according to
Wild et al. [22], and the radiopeptides were obtained in >99% radio-
chemical purity at specific activities of >37 GBq/mmol peptide. For
internalization, cellular retention, and animal biodistribution experi-
ments the DOTA-peptides were labeled with 111InCl3 to a specific
activity of about 37 GBq/mmol peptide, and then excess 115InCl3
was added to afford structurally characterized homogenous ligands.
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The octanol-water partition coefficients were determined by using
the shake flask method. Both solvents (aqueous and octanol) were
presaturated with the other by leaving them in contact for at least
24 hr. To a solution of 100 nM radiolabeled peptide (6 MBq/nmol)
in 500 ml PBS (pH 7.4), 500 ml octanol were added (n = 5). The mix-
tures were vigorously shaken on a shaker long enough to reach equi-
librium (w1 hr). After equilibration, the mixtures were centrifuged (10
min at 2000 rpm) to achieve good separation. The activity concentra-
tions in 100 ml samples of both the aqueous and the organic phase
were measured in a g-counter. The partition coefficient (log P) was
calculated from the formula:
log P = log10ðcounts in octanol layer=counts in aqueous layerÞ:
Receptor Binding Assays
CHO-K1 and CCL39 cells stably expressing human sst1–5 were
grown as described previously [14]. All culture reagents were sup-
plied by GIBCO-BRL and Life Technologies (Grand Island, NY).
Cell membrane pellets were prepared, and receptor autoradiogra-
phy was performed on pellet sections (mounted on microscope
slides), as described in detail previously [14]. For each of the tested
compounds, complete displacement experiments were performed
with the universal somatostatin radioligand [125I][Leu8, D-Trp22,
Tyr25]-somatostatin-28 by using increasing concentrations of the
MetalloIII-DOTA-peptide ranging from 0.1 to 1000 nM. Somato-
statin-28 was run in parallel as a control by using the same increas-
ing concentrations. IC50 values were calculated after quantification
of the data by using a computer-assisted image processing sys-
tem. Tissue standards (autoradiographic [125I ] microscales; Amer-
sham, UK) containing known amounts of isotopes, crosscalibrated
to tissue-equivalent ligand concentrations, were used for quantifi-
cation [14].
Cell Culture, Radioligand Internalization, and Cellular
Retention Studies
The apparatus and procedures for cell internalization and cellular re-
tention experiments are based on previously described methods
[37]. Briefly, the AR42J cell line was maintained by serial passage
in monolayers in Dulbecco’s modified Eagle’s media (DMEM), sup-
plemented with 10% fetal bovine serum, amino acids, vitamins,
and penicillin-streptomycin, in a humidified 5% CO2 atmosphere
at 37C. Human embryonic kidney 293 (HEK293) cells stably ex-
pressing rat sst3 receptors [30] were grown in DMEM supplemented
with 10% fetal bovine serum, penicillin-streptomycin, and G418
(500 mg/ml) in a humidified 5% CO2 atmosphere at 37
C. For all
cell experiments, the cells were seeded at a density of 0.8–1.1 million
cells/well in 6-well plates and were incubated overnight with inter-
nalization buffer (DMEM, 1% fetal bovine serum [pH 7.4]) to obtain
a good cell adherence. The 111/115In-labeled peptides were added
to the wells to a final concentration of 1.67 nM, and the cells were in-
cubated at 37C for the indicated time periods in triplicate. To deter-
mine nonspecific membrane binding and internalization, cells were
incubated with the radioligand in the presence of 1 mM InIII-3. The
cellular uptake was stopped by removing the medium from the cells
and by washing the cells twice with 1 ml ice-cold PBS. An acid wash
for 10 min with a glycine-buffer (pH 2.8) on ice was also performed
twice. Finally, the cells were treated with 1 N NaOH. The culture me-
dium, the surface-bound fraction, and the internalized fraction were
measured radiometrically in a g-counter.
For cellular retention studies AR4-2J cells as well as HEK cells
stably expressing sst3 (1 million) were incubated with 1.67 nM
111/115In-labeled 3 and 5 for 120 min, respectively, the medium was
then removed, and the wells were washed twice with 1 ml ice-cold
PBS. Cells were then incubated again at 37C with fresh internaliza-
tion buffer (DMEM containing 1% fetal bovine serum [pH 7.4]). After
different time points, the external medium was removed for quanti-
fication of radioactivity in a g-counter and was replaced with fresh
37C medium. The cells were solubilized in 1 N NaOH, and the inter-
nalized radioactivity was quantified in a g-counter. The washed-out
fraction collected at different time points was expressed as a per-
centage of the total internalized amount of radiopeptide per 1 million
cells.Immunocytochemistry
HEK293 cells were stably transfected with the human sst5 receptor,
as previously described [30]. After 30 min of treatment with 1 mM SS-
14, InIII-3, or and InIII-5, cells were fixed with 4% paraformaldehyde
and 0.2% picric acid in phosphate buffer (pH 6.9) for 40 min at
room temperature and were washed three times in 10 mM Tris-HCl
(pH 7.4), 10 mM phosphate buffer, 137 mM NaCl, and 0.05% thimer-
osal (TPBS). Specimens were then incubated for 3 min in 50% meth-
anol and for 3 min in 100% methanol, washed in TPBS, and preincu-
bated with TPBS supplemented with 3% normal goat serum for 1 hr
at room temperature. Cells were then incubated with affinity-purified
anti-sst5 antibody obtained as previously described [42] at a con-
centration of 1 mg/ml in TPBS supplemented with 1% normal goat
serum overnight. After washing with TPBS, bound primary antibody
was detected with cyanine 3.18-conjugated secondary antibody
(Amersham, Braunschweig, Germany). Specimens were mounted
and examined with a Leica TCS-NT laser scanning confocal micro-
scope as described [42].
Animal Biodistribution Studies
Animals were kept, treated, and cared for in compliance with the
guidelines of the Swiss regulations (approval #789).
CA20948 Rat Tumor Model
Male Lewis rats (Harlan, The Netherlands; 200–300 g), bearing the rat
CA20948 pancreatic tumor [31] in their flank, were used for the ex-
periments. An injection of 2–3 MBq of 0.34 nmol (0.5 mg total peptide
mass) 111In-3 or 111In-5 in 0.1 ml saline was administered to the dor-
sal vein of the penis of ether-anesthesized rats.
AR42J Rat Tumor Model
Five-week-old male Lewis rats were implanted subcutaneously with
10–12 million AR4-2J cells freshly suspended in sterile PBS. Four-
teen days after inoculation, the rats showed solid palpable tumor
masses (tumor weight of 0.4–0.7 g) and were used for the experi-
ments. Rats were injected under ether anesthesia with 2–3 MBq of
0.34 nmol (0.5 mg total peptide mass) 111In-3 or 111In-5 in 0.1 ml
saline; the injection was given in the femoral vein.
In both animal models, rats were sacrificed under ether anesthesia
4 hr, 24 hr, and 48 hr after injection. Organs and blood were col-
lected, and the radioactivity in these samples was determined by
using a g-counter. In order to determine the nonspecific uptake of
the radiopeptides, rats were injected with 0.5 mg octreotide in
0.1 ml saline as a coinjection with the radioligand.
Statistical Methods
To compare differences between the radiopeptides, the Student’s
t test was used.
Supplemental Data
Supplemental Data include a table with the analytical data for com-
pounds 1–24 and are available at http://www.chembiol.com/cgi/
content/full/13/10/1081/DC1/.
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